0001683168-24-001207.txt : 20240227
0001683168-24-001207.hdr.sgml : 20240227
20240227141403
ACCESSION NUMBER: 0001683168-24-001207
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230530
FILED AS OF DATE: 20240227
DATE AS OF CHANGE: 20240227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Choe Zia
CENTRAL INDEX KEY: 0002013089
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-49709
FILM NUMBER: 24685222
MAIL ADDRESS:
STREET 1: 3753 HOWARD HUGHES PARKWAY
STREET 2: SUITE 200
CITY: LAS VEGAS
STATE: NV
ZIP: 89169
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cardiff Lexington Corp
CENTRAL INDEX KEY: 0000811222
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 841044583
STATE OF INCORPORATION: FL
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3753 HOWARD HUGHES PARKWAY
STREET 2: SUITE 200
CITY: LAS VEGAS
STATE: NV
ZIP: 89169
BUSINESS PHONE: 844-628-2100
MAIL ADDRESS:
STREET 1: 3753 HOWARD HUGHES PARKWAY
STREET 2: SUITE 200
CITY: LAS VEGAS
STATE: NV
ZIP: 89169
FORMER COMPANY:
FORMER CONFORMED NAME: CARDIFF INTERNATIONAL INC
DATE OF NAME CHANGE: 20000211
FORMER COMPANY:
FORMER CONFORMED NAME: UNITED AMERICAN INC
DATE OF NAME CHANGE: 19910924
FORMER COMPANY:
FORMER CONFORMED NAME: CARDIFF FINANCIAL INC
DATE OF NAME CHANGE: 19890510
4
1
ownership.xml
X0508
4
2023-05-30
0
0000811222
Cardiff Lexington Corp
CDIX
0002013089
Choe Zia
3753 HOWARD HUGHES PARKWAY, SUITE 200
LAS VEGAS
NV
890169
0
1
0
0
Interim CFO
0
Series B Preferred Stock
2023-05-30
4
J
0
3150
0.00
A
2023-05-30
Common Stock
3150
D
On May 30, 2023, the Reporting Person received 3,150 shares of Series B Preferred Stock as partial compensation for the Reporting Person's services as Interim Chief Financial Officer of the Issuer. Each share of Series B Preferred Stock is convertible into such number of shares of Common Stock as is determined as follows: (i) if the closing market price of the Common Stock on the principal trading market on which the Common Stock is then traded or quoted is less than $4.00 per share, then each share of Series B Preferred Stock shall be convertible into a number of shares of Common Stock equal to two (2) times the stated value ($4.00 per share), divided by such closing market price on the date of conversion; or (ii) if such closing market price is equal to or greater than $4.00 per share, then each share of Series B Preferred Stock shall be convertible into two (2) shares of Common Stock. The Series B Preferred Stock has no expiration date.
/s/ Zia Choe
2024-02-27